pages_aktie_[isin]__meta_title

components_charts_RevenueChart_14	Clovis Oncology components_charts_RevenueChart_8	Clovis Oncology components_charts_RevenueChart_10	Clovis Oncology components_charts_RevenueChart_9
2024e	173.72 number_format_mio undefined	-98.39 number_format_mio undefined	-70.18 number_format_mio undefined
2023e	160.36 number_format_mio undefined	-143.83 number_format_mio undefined	-117.21 number_format_mio undefined
2022e	133.09 number_format_mio undefined	-201.28 number_format_mio undefined	-240.39 number_format_mio undefined
2021	148.76 number_format_mio undefined	-220.29 number_format_mio undefined	-264.52 number_format_mio undefined
2020	164.52 number_format_mio undefined	-302.19 number_format_mio undefined	-369.21 number_format_mio undefined
2019	143.01 number_format_mio undefined	-367.31 number_format_mio undefined	-400.42 number_format_mio undefined

	components_charts_RevenueChart_8	components_charts_RevenueChart_10	components_charts_RevenueChart_9
2019	143.01 number_format_mio USD	-367.31 number_format_mio USD	-400.42 number_format_mio USD
2020	164.52 number_format_mio USD	-302.19 number_format_mio USD	-369.21 number_format_mio USD
2021	148.76 number_format_mio USD	-220.29 number_format_mio USD	-264.52 number_format_mio USD
2022e	133.09 number_format_mio USD	-201.28 number_format_mio USD	-240.39 number_format_mio USD
2023e	160.36 number_format_mio USD	-143.83 number_format_mio USD	-117.21 number_format_mio USD
2024e	173.72 number_format_mio USD	-98.39 number_format_mio USD	-70.18 number_format_mio USD

Clovis Oncology components_charts_MarginsChart_15	Clovis Oncology components_charts_MarginsChart_16	Clovis Oncology components_charts_MarginsChart_17	Clovis Oncology components_charts_MarginsChart_16
2024e	73.9 %	-56.64 %	-40.4 %
2023e	73.9 %	-89.69 %	-73.09 %
2022e	73.9 %	-151.24 %	-180.62 %
2021	73.9 %	-148.09 %	-177.82 %
2020	74.89 %	-183.68 %	-224.41 %
2019	75.75 %	-256.85 %	-280.01 %

	components_charts_MarginsChart_15	components_charts_MarginsChart_17	components_charts_MarginsChart_16
2019	75.75 %	-256.85 %	-280.01 %
2020	74.89 %	-183.68 %	-224.41 %
2021	73.9 %	-148.09 %	-177.82 %
2022e	73.9 %	-151.24 %	-180.62 %
2023e	73.9 %	-89.69 %	-73.09 %
2024e	73.9 %	-56.64 %	-40.4 %

components_charts_RevenuePerShareChart_17	Clovis Oncology components_charts_RevenuePerShareChart_10	Clovis Oncology components_charts_RevenuePerShareChart_12	Clovis Oncology components_charts_RevenuePerShareChart_11
2024e	1.2 undefined	0 undefined	-0.48 undefined
2023e	1.11 undefined	0 undefined	-0.81 undefined
2022e	0.92 undefined	0 undefined	-1.66 undefined
2021	1.29 undefined	-1.91 undefined	-2.29 undefined
2020	1.95 undefined	-3.58 undefined	-4.38 undefined
2019	2.65 undefined	-6.82 undefined	-7.43 undefined

	components_charts_RevenuePerShareChart_10	components_charts_RevenuePerShareChart_12	components_charts_RevenuePerShareChart_11
2019	2.65 USD	-6.82 USD	-7.43 USD
2020	1.95 USD	-3.58 USD	-4.38 USD
2021	1.29 USD	-1.91 USD	-2.29 USD
2022e	0.92 USD	0 USD	-1.66 USD
2023e	1.11 USD	0 USD	-0.81 USD
2024e	1.2 USD	0 USD	-0.48 USD

components_EarningsSuprises__1	components_EarningsSuprises__2	components_EarningsSuprises__3	components_EarningsSuprises__4
9/30/2022	-0.43	-0.39 (8.39 %)	2022 Q3
6/30/2022	-0.43	-0.5 (-17.45 %)	2022 Q2
3/31/2022	-0.45	-0.44 (1.23 %)	2022 Q1
12/31/2021	-0.59	-0.48 (18.24 %)	2021 Q4
9/30/2021	-0.49	-0.56 (-13.75 %)	2021 Q3
6/30/2021	-0.58	-0.61 (-4.81 %)	2021 Q2
3/31/2021	-0.74	-0.64 (13.5 %)	2021 Q1
12/31/2020	-0.79	-1.02 (-28.61 %)	2020 Q4
9/30/2020	-1.02	-0.89 (12.86 %)	2020 Q3
6/30/2020	-1.08	-1.15 (-6.9 %)	2020 Q2
3/31/2020	-1.32	-1.28 (2.83 %)	2020 Q1
12/31/2019	-1.76	-1.81 (-2.94 %)	2019 Q4
9/30/2019	-1.95	-1.78 (8.61 %)	2019 Q3
6/30/2019	-1.77	-2.27 (-28.58 %)	2019 Q2
3/31/2019	-1.79	-1.63 (9.05 %)	2019 Q1
12/31/2018	-1.78	-1.88 (-5.81 %)	2018 Q4
9/30/2018	-1.64	-1.71 (-4.08 %)	2018 Q3
6/30/2018	-1.93	-1.94 (-0.34 %)	2018 Q2
3/31/2018	-1.41	-1.54 (-9.58 %)	2018 Q1
12/31/2017	-1.34	-1.04 (22.42 %)	2017 Q4
9/30/2017	-1.25	-1.24 (1.02 %)	2017 Q3
6/30/2017	-2.2	-1.29 (41.32 %)	2017 Q2
3/31/2017	-1.53	-1.33 (12.88 %)	2017 Q1
12/31/2016	-1.69	-1.83 (-8.03 %)	2016 Q4
9/30/2016	-2.01	-1.7 (15.31 %)	2016 Q3
6/30/2016	-2.16	-2.07 (4.08 %)	2016 Q2
3/31/2016	-2.46	-2.17 (11.94 %)	2016 Q1
12/31/2015	-2.51	-2.23 (11.19 %)	2015 Q4
9/30/2015	-2.13	-2.62 (-23.08 %)	2015 Q3
6/30/2015	-2.05	-2.1 (-2.38 %)	2015 Q2
3/31/2015	-1.87	-1.86 (0.51 %)	2015 Q1
12/31/2014	-1.33	-1.62 (-21.45 %)	2014 Q4
9/30/2014	-1.1	-1.17 (-6.44 %)	2014 Q3
6/30/2014	-0.99	-1.03 (-4.57 %)	2014 Q2
3/31/2014	-0.87	-0.91 (-4.47 %)	2014 Q1
12/31/2013	-0.8	-0.92 (-14.51 %)	2013 Q4
9/30/2013	-0.7	-0.68 (2.21 %)	2013 Q3
6/30/2013	-0.67	-0.72 (-7.77 %)	2013 Q2
3/31/2013	-0.62	-0.6 (3.44 %)	2013 Q1
12/31/2012	-0.81	-0.81 (-0.4 %)	2012 Q4
9/30/2012	-0.69	-0.71 (-2.38 %)	2012 Q3
6/30/2012	-0.63	-0.61 (2.91 %)	2012 Q2
3/31/2012	-0.75	-0.86 (-14.38 %)	2012 Q1
12/31/2011	-0.81	-1.3 (-59.76 %)	2011 Q4

components_OwnershipTable__4	components_OwnershipTable__0	components_OwnershipTable__1	components_OwnershipTable__2	components_OwnershipTable__3
0.67 %	Mahaffy (Patrick J)	970,787	0	4/11/2022
0.45 %	Aberdare Ventures	651,833	12,755	4/11/2022
0.34 %	Healthcare Value Capital, LLC	500,000	0	9/30/2021
0.28 %	AXA Rosenberg Investment Management LLC	401,300	401,300	12/31/2021
0.20 %	Ivers-Read (Gillian C)	293,612	4,693	11/2/2022
0.18 %	McKinley (Edward J)	268,016	0	4/11/2022
0.17 %	Macquarie Investment Management	250,200	0	12/31/2022
0.08 %	Rolfe (Lindsey)	113,691	4,113	11/2/2022
0.08 %	Signal Iduna Asset Management GmbH	110,000	61,000	12/31/2022
0.07 %	Muehl (Daniel W)	104,830	5,669	11/2/2022
0.07 %	Gross (Paul Edward)	98,330	5,518	11/2/2022
0.06 %	Global X Management (AUS) Limited	84,432	3,019	2/28/2022
0.04 %	Blair (James C)	63,544	0	4/11/2022
0.04 %	Stewart Capital Advisors, LLC	60,000	20,000	12/31/2022
0.04 %	Klingenstein (Paul H)	59,327	-12,755	4/11/2022
0.04 %	Atwood (Brian G)	58,973	0	4/11/2022
0.04 %	Spickschen (Thorlef)	58,176	0	4/11/2022
0.02 %	Harding (Thomas C)	22,318	1,671	11/2/2022
0.01 %	Wedbush Securities, Inc.	20,200	0	12/31/2022
0.01 %	MAI Capital Management, LLC	20,000	0	12/31/2022
0.01 %	Amalgamated Financial Corp.	18,424	18,424	3/31/2022
0.01 %	Principal Funds, Inc.	17,378	-3,272	4/30/2022
0.01 %	Gesiuris Asset Management S.G.I.I.C., S.A.	15,000	15,000	12/31/2022
0.01 %	Future Financial Wealth Management Group LLC	13,500	0	12/31/2022
0.01 %	Newbridge Capital Management	12,500	0	12/31/2022
0.01 %	Qube Research & Technologies Ltd	11,980	-8,098	12/31/2022
0.01 %	Diem Client Partner AG	11,500	0	8/31/2021
0.01 %	Independent Financial Partners	10,050	50	12/31/2022
0.00 %	Mackenzie Financial Corporation	6,200	6,200	9/30/2022
0.00 %	Welzia Management SGIIC S.A.	4,379	4,379	12/31/2021
0.00 %	Westfield Capital Management Company, L.P.	4,071	0	9/30/2021
0.00 %	GF Fund Management Co., Ltd.	3,282	1,258	6/30/2022
0.00 %	Tinkoff Capital OOO	953	47	12/31/2021
0.00 %	NEXT Financial Group, Inc.	750	0	12/31/2021
0.00 %	Guggenheim Investments	672	0	11/30/2022
0.00 %	Tower Research Capital LLC	660	-10,029	12/31/2022
0.00 %	San Francisco Sentry Investment Group	600	0	6/30/2021
0.00 %	Rockefeller Capital Management	375	-6,000	12/31/2022
0.00 %	Berman Capital Advisors, LLC	256	256	9/30/2021
0.00 %	RMC Investment Advisors	250	0	12/31/2022
0.00 %	Quent Capital, LLC	231	0	12/31/2022
0.00 %	Exane Derivatives	166	0	6/30/2022
0.00 %	Kozak & Tripp Private Asset Management, Inc.	140	0	12/31/2022
0.00 %	Schroder Investment Management (Australia) Ltd.	8	8	9/30/2021
0 %	Clearstead Advisors LLC	0	-400	9/30/2021
0 %	Advisor Group, Inc	0	-38,505	12/31/2022
0 %	Wolverine Trading, LLC	0	-45,133	9/30/2022
0 %	L2 Asset Management, LLC	0	-248	11/30/2022
0 %	Parallel Advisors, LLC	0	-100	12/31/2022
0 %	Ellevest, Inc.	0	-361	12/31/2021
0 %	Sowell Management Services	0	-4,520	6/30/2021
0 %	Steward Partners Investment Advisory, LLC	0	-2,500	6/30/2021
0 %	MetLife Investment Management, LLC	0	-43,789	3/31/2022
0 %	Ergoteles Capital	0	-707,300	9/30/2022
0 %	HAP Trading, LLC	0	-54,014	12/31/2021
0 %	Valeo Financial Advisors LLC	0	-12,500	9/30/2021
0 %	Perigon Wealth Management, LLC	0	-61,093	12/31/2022
0 %	Squarepoint Capital LLP	0	-16,700	12/31/2022
0 %	Advisory Services Network, LLC	0	-320	9/30/2021
0 %	PDT Partners, LLC	0	-11,261	9/30/2021
0 %	Athanor Capital, LP	0	-13,415	6/30/2021
0 %	Schonfeld Strategic Advisors LLC	0	-10,300	3/31/2022
0 %	Cresset Asset Management, LLC	0	-18,367	12/31/2021
0 %	First Command Advisory Services, Inc.	0	-6	6/30/2022
0 %	TCI Wealth Advisors, Inc.	0	-2,340	6/30/2022
0 %	Carson Wealth Management Group	0	-310	12/31/2022
0 %	MainStreet Advisors	0	-1,000	12/31/2021
0 %	CSS, LLC	0	-6,000	6/30/2021
0 %	Point72 Hong Kong Limited	0	-1,267	9/30/2022
0 %	Cahill Financial Advisors, Inc.	0	-393	12/31/2021
0 %	Cubist Systematic Strategies, LLC	0	-10,367	9/30/2022
0 %	LPL Financial LLC	0	-14,133	12/31/2022
0 %	AHL Partners LLP	0	-12,535	12/31/2022
0 %	Old Mission Capital LLC	0	-15,509	6/30/2021
0 %	Valley National Advisers Inc.	0	-1,505	12/31/2022
0 %	HRT Financial LP	0	-130,830	9/30/2022
0 %	McIlrath & Eck, LLC	0	-500	12/31/2022
0 %	Koshinski Asset Management, Inc	0	-7,600	12/31/2021
0 %	Trexquant Investment LP	0	-23,732	9/30/2021
0 %	Engineers Gate Manager, L.P.	0	-13,406	12/31/2022
0 %	Cypress Capital Management, LLC (WY)	0	-200	9/30/2022
0 %	Penserra Capital Management LLC	0	-2,705	12/31/2021
0 %	Boothbay Fund Management, LLC	0	-36,350	12/31/2022
0 %	Pacer Advisors, Inc.	0	-13,131	6/30/2021
0 %	Simplex Trading, LLC	0	-99,358	9/30/2022
0 %	Dynamic Technology Lab Pte. Ltd.	0	-38,990	3/31/2022
0 %	Frontier Wealth Management LLC	0	-27,575	9/30/2021
0 %	MML Investors Services, LLC	0	-72,135	12/31/2021
0 %	Ikarian Capital LLC	0	-361,518	12/31/2022
0 %	Alpine Global Management, LLC	0	-45,990	3/31/2022
0 %	Virtus Etf Advisers LLC	0	-57,437	6/30/2022
0 %	Eversept Partners, LP	0	-30,000	6/30/2022
0 %	BMO Family Office, LLC	0	-21,352	6/30/2022
0 %	Vector Wealth Management	0	-10,000	12/31/2022
0 %	Stuart Chaussee & Associates, Inc.	0	-2,675	6/30/2021
0 %	Kalos Management, Inc.	0	-10,500	9/30/2022
0 %	BerganKDV Wealth Management, LLC	0	-50	3/31/2022
0 %	Caption Management, LLC	0	-182,455	9/30/2022
0 %	ExodusPoint Capital Management, LP	0	-155,020	6/30/2022
0 %	Susquehanna Fundamental Investments, LLC	0	-115,299	12/31/2022

Clovis Oncology代表什么价值观和企业理念？

Clovis Oncology Inc代表的是创新、协作与热情的价值观。该公司致力于为患有复杂癌症的患者提供创新治疗方案，改善他们的生活质量。Clovis Oncology Inc的企业理念是通过持续的研究和探索，开发高效的肿瘤治疗药物，以满足患者和医疗专业人员的需求。这家公司通过与全球合作伙伴紧密合作，追求卓越并不断突破边界，以加速新药物的发现和发展。Clovis Oncology Inc坚信，通过科学创新和患者为中心的理念，可以为患者带来更长寿命和更好的生活质量。

Clovis Oncology主要存在于哪些国家和地区？

Clovis Oncology Inc主要存在于美国。

公司Clovis Oncology已经达到了哪些重要的里程碑？

截至目前，Clovis Oncology Inc已经达到了几个重要的里程碑。首先，该公司的PARP抑制剂Rucaparib已获得美国食品和药物管理局（FDA）批准，并用于治疗卵巢癌患者。此外，Clovis Oncology Inc还成功推出了Rubraca Companion Diagnostic测试，该测试可用于检测卵巢癌患者是否适合接受Rucaparib治疗。此外，该公司还与Bristol-Myers Squibb合作，进行临床试验，探索Rucaparib和其他药物的联合治疗潜力。这些里程碑的达成为Clovis Oncology Inc在肿瘤领域的发展奠定了坚实的基础。

Clovis Oncology公司有什么故事和背景？

Clovis Oncology Inc公司的故事和背景是什么？ Clovis Oncology Inc是一家专注于肿瘤治疗的生物医药公司。该公司致力于开发和商业化抗癌药物，以满足患者和医生的需求。Clovis Oncology Inc的使命是通过创新治疗病人的癌症，并提高他们的生活质量。该公司的研发重点是针对特定类型癌症的个体化治疗方案，以便为每位病人提供最佳的治疗方案。Clovis Oncology Inc的目标是成为癌症治疗领域的领导者，并为肿瘤患者提供创新的治疗选择。该公司的产品和研究努力不断推动癌症治疗领域的进步，为患者和医疗社区带来新的希望。

Clovis Oncology在市场上的主要竞争对手是谁？

Clovis Oncology Inc在市场上的主要竞争对手是AstraZeneca。

Clovis Oncology 主要从事哪些行业？

Clovis Oncology Inc（克劳维斯肿瘤学有限公司）是一家主要从事肿瘤相关医药研究和开发的公司。该公司致力于研制创新的抗癌药物，专注于癌症治疗领域。Clovis Oncology Inc的核心业务是发现、开发和商业化创新的癌症治疗方案，为患者提供更有效和个性化的抗癌药物。该公司的研究和开发项目涵盖多个肿瘤类型，旨在提供更好的治疗选择和提高患者的生存率。Clovis Oncology Inc在肿瘤治疗领域展示出良好的潜力，并致力于为患者带来新的疗法和希望。

Clovis Oncology的商业模式是什么？

Clovis Oncology Inc的商业模式是专注于研发、生产和销售抗癌药物的生物制药公司。该公司致力于开发创新的肿瘤治疗方案，为患者提供更好的治疗选择。Clovis Oncology Inc注重科技创新，拥有强大的研发团队和专利技术，不断推出具有潜在市场价值的抗癌药物。通过与医疗机构和生物技术公司的合作，Clovis Oncology Inc积极寻求药物组合治疗策略，以提高抗癌药物的疗效和生存率。该公司的商业模式致力于为肿瘤患者提供创新的治疗选择，不断推动肿瘤学和抗癌药物领域的进步。

pages_aktie_[isin]__11

pages_aktie_[isin]__12

pages_aktie_[isin]__14

pages_aktie_[isin]__15

pages_aktie_[isin]__17

pages_aktie_[isin]__18

pages_aktie_[isin]__20

pages_aktie_[isin]__21

pages_aktie_[isin]__23

pages_aktie_[isin]__24

pages_aktie_[isin]__26

pages_aktie_[isin]__27

pages_aktie_[isin]__29

pages_aktie_[isin]__30

pages_aktie_[isin]__32

pages_aktie_[isin]__34

pages_aktie_[isin]__35

pages_aktie_[isin]__36

pages_aktie_[isin]__37

pages_aktie_[isin]__38

pages_aktie_[isin]__39

pages_aktie_[isin]__40

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_ESGRating_35	—
components_ESGRating_36	—
components_ESGRating_37	—
components_ESGRating_38	—
components_ESGRating_11	✅
components_ESGRating_39	❌
components_ESGRating_47	❌
components_ESGRating_24	✅
components_ESGRating_42	—
components_ESGRating_49	—
components_ESGRating_48	—
components_ESGRating_50	❌
components_ESGRating_44	❌
components_ESGRating_8	—
components_ESGRating_12	—
components_ESGRating_13	❌
components_ESGRating_16	❌
components_ESGRating_17	❌
components_ESGRating_18	❌
components_ESGRating_19	❌

components_ESGRating_20	—
components_ESGRating_21	—
components_ESGRating_25	—
components_ESGRating_26	—
components_ESGRating_29	—
components_ESGRating_30	—
components_ESGRating_27	—
components_ESGRating_28	—
components_ESGRating_31	—
components_ESGRating_32	—
components_ESGRating_22	❌
components_ESGRating_23	❌
components_ESGRating_51	—
components_ESGRating_41	❌
components_ESGRating_43	❌
components_ESGRating_46	❌
components_ESGRating_9	❌
components_ESGRating_10	—
components_ESGRating_15	✅
components_ESGRating_33	✅

components_ESGRating_40	❌
components_ESGRating_34	❌
components_ESGRating_45	❌
components_ESGRating_14	❌

components_Profile_Tickers_1	Clovis Oncology components_Profile_Tickers_2
COMPONENTS_PROFILE_TICKERS_25	C6O.DU
COMPONENTS_PROFILE_TICKERS_23	C6O.F
LONDON	0A7C.L
COMPONENTS_PROFILE_TICKERS_13	C6O.MU
NASDAQ	CLVS
SIX	C6O.SW
XETRA	C6O.DE

Clovis Oncology components_Profile_Tickers_2	Clovis Oncology FIGI
CLVSEUR:EO	BBG008B8PPG2
CLVSEUR:XH	BBG008B8PPK7
CLVSEUR:XF	BBG008B8PPM5
CLVSEUR:XE	BBG008B8PPP2
CLVSEUR:XJ	BBG008B8PPQ1
CLVSEUR:XL	BBG008B8PPR0
CLVSEUR:XG	BBG008B8PPS9
CLVSEUR:XO	BBG008B8PPT8
CLVSEUR:XS	BBG008B8PPY2
CLVSEUR:XA	BBG008B8PPZ1
CLVSEUR:E1	BBG008B8PQ07
CLVSEUR:XT	BBG008B8PQ16
CLVSEUR:XW	BBG008B8PQ25
CLVSEUR:XU	BBG008B8PQ34
CLVSEUR:XV	BBG008B8PQ52
CLVSEUR:EU	BBG008B8PQ70
CLVSEUR:XX	BBG00JN8BS38
CLVSUSD:X2	BBG00JPVNMS8
CLVSUSD:XB	BBG00JPVNMT7
CLVSUSD:XH	BBG00JPVNMW3
CLVSUSD:XF	BBG00JPVNMY1
CLVSUSD:XE	BBG00JPVNN06
CLVSUSD:XJ	BBG00JPVNN15
CLVSUSD:XL	BBG00JPVNN24
CLVSUSD:XG	BBG00JPVNN33
CLVSUSD:XO	BBG00JPVNN42
CLVSUSD:XS	BBG00JPVNN88
CLVSUSD:XA	BBG00JPVNN97
CLVSUSD:E1	BBG00JPVNNB4
CLVSUSD:XT	BBG00JPVNNC3
CLVSUSD:XW	BBG00JPVNND2
CLVSUSD:XU	BBG00JPVNNF0
CLVSUSD:XV	BBG00JPVNNG9
CLVSUSD:XM	BBG00JPVNNH8
CLVSUSD:XQ	BBG00JPVNNK4
CLVSUSD:XX	BBG00JPVNNL3
CLVSUSD:XZ	BBG00JPVNNM2
CLVSUSD:EU	BBG00JPVNNP9
CLVSGBP:X2	BBG00JZ3BRG4
CLVSGBP:XB	BBG00JZ3BRH3
CLVSGBP:XH	BBG00JZ3BRK9
CLVSGBP:XF	BBG00JZ3BRM7
CLVSGBP:XE	BBG00JZ3BRP4
CLVSGBP:XJ	BBG00JZ3BRQ3
CLVSGBP:XL	BBG00JZ3BRR2
CLVSGBP:XG	BBG00JZ3BRS1
CLVSGBP:XO	BBG00JZ3BRT0
CLVSGBP:XS	BBG00JZ3BRY4
CLVSGBP:XA	BBG00JZ3BRZ3
CLVSGBP:E1	BBG00JZ3BS09
CLVSGBP:XT	BBG00JZ3BS18
CLVSGBP:XW	BBG00JZ3BS27
CLVSGBP:XU	BBG00JZ3BS36
CLVSGBP:XV	BBG00JZ3BS45
CLVSGBP:XM	BBG00JZ3BS54
CLVSGBP:XQ	BBG00JZ3BS72
CLVSGBP:XX	BBG00JZ3BS81
CLVSGBP:XZ	BBG00JZ3BS90
CLVSGBP:EU	BBG00JZ3BSC6
CLVSN:PO	BBG00QV3FWD0
CLVSN:L3	BBG00QV3GKB7
CLVSN:B3	BBG00QV3GT73
CLVSUSD:EP	BBG00QV3HFB7
CLVSUSD:EZ	BBG00QV3HFD5
CLVSN:L1	BBG00Y7BNG39

components_HeaderAdBanner_2

components_StockPageHeader__12

components_StockPageHeaderMobile__3

components_StockPageHeader__3C6O.F

components_StockPageHeader__4US1894641000

components_StockPageHeader__5A1JPJY

components_charts_RevenueChart_0 US1894641000 · A1JPJY

Clovis Oncology components_charts_RevenueChart_15

Clovis Oncology components_StockTable__14

components_PaywallOverlay_0

components_charts_MarginsChart_0 US1894641000 · A1JPJY

Clovis Oncology components_charts_MarginsChart_21

components_charts_RevenuePerShareChart_0 US1894641000 · A1JPJY

Clovis Oncology components_charts_RevenuePerShareChart_18

pages_aktie_[isin]__4

pages_aktie_[isin]__7

components_PaywallOverlay_0

Clovis Oncology components_EstimatedEarnings__0

Clovis Oncology components_EarningsSuprises__0

components_ESGRating_0

Eulerpool ESG Rating (EESG©)

59/ 100

🌱 Environment

👫 Social

🏛️ Governance

components_ESGRating_1

components_ESGRating_2

components_ESGRating_3

components_PaywallOverlay_0

pages_aktie_[isin]__9

Clovis Oncology components_CompanyExecutives__0

pages_aktie_[isin]__1

Clovis Oncology代表什么价值观和企业理念？

Clovis Oncology主要存在于哪些国家和地区？

公司Clovis Oncology已经达到了哪些重要的里程碑？

Clovis Oncology公司有什么故事和背景？

Clovis Oncology在市场上的主要竞争对手是谁？

Clovis Oncology 主要从事哪些行业？

Clovis Oncology的商业模式是什么？

pages_aktie_[isin]__11

pages_aktie_[isin]__14

pages_aktie_[isin]__17

pages_aktie_[isin]__20

pages_aktie_[isin]__23

pages_aktie_[isin]__26

pages_aktie_[isin]__29

pages_aktie_[isin]__32

pages_aktie_[isin]__35

pages_aktie_[isin]__37

pages_aktie_[isin]__39

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_10

Wann musste ich die Aktien von Clovis Oncology kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_21

components_Profile_KeyStats__31

components_Profile_CompanyPeers_0

components_Profile_EulerpoolNews__0

components_Profile_NewsAndPressReleases__0

Clovis Oncology components_Profile_Tickers_0

Clovis Oncology FIGI

pages_aktie_[isin]__10

components_GenericText_0

components_GenericText_1

components_GenericText_5

components_GenericText_7

components_GenericText_10

components_GenericText_12

components_GenericText_15

components_GenericText_16

components_GenericText_18

components_GenericText_20

components_GenericText_22

components_GenericText_24

components_GenericText_27

components_StockPageHeader__3
C6O.F

components_StockPageHeader__4
US1894641000

components_StockPageHeader__5
A1JPJY